Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + capecitabine + oxaliplatin followed by SHR-1210 + apatinib vs capecitabine + oxaliplatin in advanced gastric/GEJ cancer
CTR20190072Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Jan 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20190072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190072.